Interaction kinetic characterization of HIV-1 reverse transcriptase non-nucleoside inhibitor resistance

Journal of Medicinal Chemistry

Volumn 49, Issue 8, 2006, Pages 2375-2387

  Geitmann, Matthis ^a   Unge, Torsten ^a   Danielson, U Helena ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

6 CHLORO 4 (2 CYCLOPROPYLVINYL) 3,4 DIHYDRO 4 TRIFLUOROMETHYL 2(1H) QUINAZOLINONE; CAPRAVIRINE; DELAVIRDINE; EFAVIRENZ; MIV 150; MSC 194; MSC 197; MSC 198; MSC 204; MSK 105; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TALVIRALINE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ARTICLE; DRUG INHIBITION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; KINETICS; SURFACE PLASMON RESONANCE;

BINDING SITES; BIOSENSING TECHNIQUES; CRYSTALLOGRAPHY, X-RAY; DRUG RESISTANCE, VIRAL; ENZYME ACTIVATION; HIV-1 REVERSE TRANSCRIPTASE; KINETICS; MOLECULAR STRUCTURE; PROTEIN CONFORMATION; PROTEIN STRUCTURE, TERTIARY; REVERSE TRANSCRIPTASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33646078264     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0504050     Document Type: Article

References (41)

1. Baba, M.; Tanaka, H.; De Clercq, E.; Pauwels, R.; Balzarini, J.; Schols, D.; Nakashima, H.; Perno, C. F.; Walker, R. T.; Miyasaka, T. Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative. Biochem Biophys Res Commun. 1989, 165, 1375-1381.
2. Pauwels, R.; Andries, K.; Desmyter, J.; Schols, D.; Kukla, M. J.; Breslin, H. J.; Raeymaeckers, A.; Van Gelder, J.; Woestenborghs, R.; Heykants, J.; Schellekens, K.; Janssen, M. A. C.; De Clercq, E.; Janssen, P. A. J. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature 1990, 343, 470-474.
3. Merluzzi, V. J.; Hargrave, K. D.; Labadia, M.; Grozinger, K.; Skoog, M.; Wu, J. C.; Shih, C. K.; Eckner, K.; Hattox, S.; Adams, J.; Rosenthal, A. S.; Faanes, R.; Eckner, R. J.; Koup, R. A.; Sullivan, J. L. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science 1990, 250, 1411-1413.
4. De Clercq, E. Nonnucleoside reverse transcriptase inhibitors (NNRTIs): Past, present, future. Chem. Biodiversity 2004, 1, 44-64.
5. Balzarini, J. Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1. Curr. Top. Med. Chem. 2004, 4, 921-944.
6. Buckheit, R. W. Non-nucleoside reverse transcriptase inhibitors: perspectives on novel therapeutic compounds and strategies for the treatment of HIV infection. Expert Opin. Investig. Drugs 2001, 10, 1423-1442.
7. Pauwels, R. New non-nucleoside reverse transcriptase inhibitors (NNRTIs) in development for the treatment of HIV infections. Curr. Opin. Pharmacol. 2004, 4, 437-446.
8. Esnouf, R.; Ren, J.; Ross, C.; Jones, Y.; Stammers, D.; Stuart, D. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Nat. Struct. Biol. 1995, 2, 303-308.
9. Rodgers, D. W.; Gamblin, S. J.; Harris, B. A.; Ray, S.; Culp, J. S.; Hellmig, B.; Woolf, D. J.; Debouck, C.; Harrison, S. C. The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 1222-1226.
10. Hsiou, Y.; Ding J.; Das K.; Clark, A. D., Jr.; Hughes, S. H.; Arnold, E. Structure of unliganded HIV-1 reverse transcriptase at 2.7 Å resolution: implications of conformational changes for polymerization and inhibition mechanisms. Structure 1996, 4, 853-860.
11. Kohlstaedt, L. A.; Wang, J.; Friedman, J. M.; Rice, P. A.; Steitz, T. A. Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992, 256, 1783-1790.
12. Ren, J.; Esnouf, R.; Garman, E.; Somers, D.; Ross, C.; Kirby, I.; Keeling, J.; Darby, G.; Jones, Y.; Stuart, D.; Stammers, D. High-resolution structures of HIV-1 RT from four RT-inhibitor complexes. Nat. Struct. Biol. 1995, 2, 293-302.
13. Spence, R. A.; Kati, W. M.; Anderson, K. S.; Johnson, K. A. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science 1995, 267, 988-993.
14. Palella, F. J., Jr.; Delaney, K. M.; Moorman, A. C.; Loveless, M. O.; Fuhrer, J.; Satten, G. A.; Aschman, D. J.; Holmberg, S. D. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med. 1998, 338, 853-860.
15. Mocroft, A.; Vella, S.; Benfield, T. L.; Chiesi, A.; Miller, V.; Gargalianos, P.; d'Arminio Monforte, A.; Yust, I.; Bruun, J. N.; Phillips, A. N.; Lundgren, J. D. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998, 352, 1725-1730.
16. Schinazi, R. F.; Larder, B. A.; Mellors, J. W. Mutations in retroviral genes associated with drug resistance. Int. Antivir. News 2000, 8, 65-91.
17. De Clercq, E. Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Il Farmaco 1999, 54, 26-45.
18. Bacheler, L. T.; Anton, E. D.; Kudish, P.; Baker, D.; Bunville, J.; Krakowski, K.; Boiling, L.; Aujay, M.; Wang, X. V.; Ellis, D.; Becker, M. F.; Lasut, A. L.; George, H. J.; Spalding, D. R.; Hollis, G.; Abremski, K. Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrob. Agents Chemother. 2000, 44, 2475-2484.
19. Das, K.; Ding, J.; Hsiou, Y.; Clark, A. D., Jr.; Moereels, H.; Koymans, L.; Andries, K.; Pauwels, R.; Janssen, P. A.; Boyer, P. L.; Clark, P.; Smith, R. H., Jr.; Kroeger Smith, M. B.; Michejda, C. J.; Hughes, S. H.; Arnold, E. Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant. J. Mol Biol. 1996, 264, 1085-1100.
20. Ren, J.; Nichols, C.; Bird, L.; Chamberlain, P.; Weaver, K.; Short, S.; Stuart, D. I.; Stammers, D. K. Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation nonnucleoside inhibitors. J. Mol. Blol. 2001, 312, 795-805.
21. Hsiou, Y.; Ding, J.; Das, K.; Clark, A. D., Jr.; Boyer, P. L.; Lewi, P.; Janssen, P. A.; Kleim, J. P.; Rosner, M.; Hughes, S. H.; Arnold, E. The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance. J. Mol. Biol. 2001, 509, 437-445.
22. Maga, G.; Amacker, M.; Ruel, N.; Hubscher, U.; Spadafi, S. Resistance to nevirapine of HIV-1 reverse transcriptase mutants: loss of stabilizing interactions and thermodynamic or steric barriers are induced by different single amino acid substitutions. J. Mol. Biol. 1997, 274, 738-747.
23. Fujiwara, T.; Sato, A.; el-Farrash, M.; Miki, S.; Abe, K.; Isaka, Y.; Kodama, M.; Wu, Y.; Chen, L. B.; Harada, H.; Sugimoto, H.; Hatanaka, M.; Hinuma, Y. S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 1998, 42, 1340-1345.
24. Andries, K.; Azijn, H.; Thielemans, T.; Ludovici, D.; Kukla, M.; Heeres, J.; Janssen, P.; De Corte, B.; Vingerhoets, J.; Pauwels, R.; de Bethune, M. P. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 2004, 48, 4680-4686.
25. Geitmann, M.; Unge, T.; Danielson, U. H. Biosensor-based kinetic characterization of the interaction between HIV-1 reverse transcriptase and non-nucleoside inhibitors. J. Med. Chem. 2006, 49, 2367-2374.
26. Temiz, N. A.; Bahar, I. Inhibitor binding alters the directions of domain motions in HIV-1 reverse transcriptase. Proteins 2002, 49, 61-70.
27. Venezia, C. F.; Howard, K. J.; Ignatov, M. E.; Holladay, L. A.; Barkley, M. D. Effects of Efavirenz Binding on the Subunit Equilibria of HIV-1 Reverse Transcriptase. Biochemistry 2006 45, 2779-2789.
28. Lindberg, J.; Sigurdsson, S.; Löwgren, S.; Andersson, H. O.; Sahlberg, C.; Noréen, R.; Fridborg, K.; Zhang, H.; Unge, T. Structural basis for the inhibitory efficacy of efavirenz (DMP-266), MSC194 and PNU142721 towards the HIV-1 RT K103N mutant. Eur. J. Biochem. 2002, 269, 1670-1677.
29. Shen, L.; Shen, J.; Luo, X.; Cheng, F.; Xu, Y.; Chen, K.; Arnold, E.; Ding, J.; Jiang, H. Steered molecular dynamics simulation on the binding of NNRTI to HIV-1 RT. Biophys. J. 2003, 84, 3547-3563.
30. Ren, J.; Nichols, C; Bird, L. E.; Fujiwara, T.; Sugimoto, H.; Stuart, D. I.; Stammers, D. K. Binding of the second generation nonnucleoside inhibitor S-1153 to HIV-1 reverse transcriptase involves extensive main chain hydrogen bonding. J. Biol. Chem. 2000, 275, 14316-14320.
31. Das, K.; Clark, A. D., Jr.; Lewi, P. J.; Heeres, J.; De Jonge, M. R. Koymans, L. M.; Vinkers, H. M.; Daeyaert, F.; Ludovici, D. W. Kukla, M. J.; De Corte, B.; Kavash, R. W.; Ho, C. Y.; Ye, H. Lichtenstein, M. A.; Andries, K.; Pauwels, R.; De Bethune, M. P. Boyer, P. L.; Clark, P.; Hughes, S. H.; Janssen, P. A.; Arnold, E. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J. Med. Chem. 2004, 47, 2550-2560.
32. Das, K.; Lewi, P. J.; Hughes, S. H.; Arnold, E. Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors. Prog. Biophys. Mol. Biol. 2005, 88, 209-231.
33. Chan, J. H.; Hong, J. S.; Hunter, R. N., 3rd; Orr, G. F.; Cowan, J. R.; Sherman, D. B.; Sparks, S. M.; Reitter, B. E.; Andrews, C. W., 3rd; Hazen, R. J.; St. Clair, M.; Boone, L. R.; Ferris, R. G.; Creech, K. L.; Roberts, G. B.; Short, S. A.; Weaver, K.; Ott, R. J.; Ren, J.; Hopkins, A.; Stuart, D. I.; Stammers, D. K.2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J. Med. Chem. 2001, 44, 1866-1882.
34. Ludovici, D. W.; Kukla, M. J.; Grous, P. G.; Krishnan, S.; Andries, K.; de Bethune, M. P.; Azijn, H.; Pauwels, R.; De Clercq, E.; Arnold, E.; Janssen, P. A. Evolution of anti-HIV drug candidates. Part 1: From alpha- anilinophenylacetamide (alpha-APA) to imidoyl thiourea (ITU). Bioorg. Med. Chem. Lett. 2001, 11, 2225-2228.
35. Jeffrey, S.; Corbett, J.; Bacheler, L. 6th Conf. Retrovir. Opportun. Infect. 1999, 6, 88 (Abstr 110).
36. Balzarini, J.; Pelemans, H.; Perez-Perez, M. J.; San-Felix, A.; Camarasa, M. J.; De Clercq, E.; Karlsson, A. Marked inhibitory activity of non-nucleoside reverse transcriptase inhibitors against human immunodeficiency virus type 1 when combined with (-)-2′,3′-dideoxy-3′-thiacytidine. Mol. Pharmacol. 1996, 49, 882-890.
37. Corbett, J. W.; Ko, S. S.; Rodgers, J. D.; Jeffrey, S.; Bacheler, L. T.; Klabe, R. M.; Diamond, S.; Lai, C. M.; Rabel, S. R.; Saye, J. A.; Adams, S. P.; Trainor, G. L.; Anderson, P. S.; Erickson-Viitanen, S. K. Expanded-spectrum nonnucleoside reverse transcriptase inhibitors inhibit clinically relevant mutant variants of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 1999, 43, 2893-2897.
38. Jeffrey, S.; Baker, D.; Corbett, J.; Logue, K.; Bacheler, L. T. 39th ICAAC Abstr. 1999, 39, 495 (Abstr 1172).
39. Balzarini, J.; Pelemans, H.; Riess, G.; Roesner, M.; Winkler, I.; De Clercq, E.; KIeim, J. P. Retention of marked sensitivity to (S)-4- isopropoxycarbonyl-6-methoxy-3-(methylthiomethyl)-3,4-di hydroquin oxaline-2(IH)-thione (HBY 097) by an azidothymidine (AZT)-resistant human immunodeficiency virus type 1 (HIV-1) strain subcultured in the combined presence of quinoxaline HBY 097 and 2′,3′-dideoxy-3′- thiacytidine (lamivudine). Biochem. Pharmacol. 1998, 55, 617-625.
40. Vrang, L.; Medivir, A. B., Huddinge, Sweden. Personal communication.
41. Högberg, M.; Sahlberg, C.; Engelhardt, P.; Noréen, R.; Kangasmetsä, J.; Johansson, N. G.; Öberg, B.; Vrang, L.; Zhang, H.; Sahlberg, B.-L.; Unge, T.; Lövgren, S.; Fridborg, K.; Bäckbro, K. Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors: Synthesis and further structure-activity relationship studies of PETT analogues, J. Med. Chem. 1999, 42, 4150-4160.